Video

Traffic Pollution Can Inscreas Your Blood Pressure

A Texas Playground Caters Especially to Special Needs Children

BPA in Plastics May be Linked to Asthma

Communication Is Important When It Comes to Prostate Cancer

The Number of Home Births Has Gone Up

Which American Couples Are More Likely to Stay Together?

Workplace Wellness Can Help Reduce the Risk for Heart Problems

Some Parents May Hasten Death for Terminally Ill Children

Fitness Academics

Secondhand Smoke Increases Risk for Heart Disease in Kids

Toddlers Don't Learn Vocabulary From TV

Despite Worries, Most Parents Vaccinate Their Kids Anyway

Food Allergies Can Be Treated With the Allergen Foods

Signs of Heart Disease Could Be As Early as 3 in Obese Kids

The Number of Women Having Strokes is Rising

Breast Cancer Drugs May Fight Cervical Cancer, Too

Posted on 11/09/2009, 17:00
By -- Robert Preidt

Study in mice reports success with drugs that inhibit estrogen

MONDAY, Nov. 9 (HealthDay News) -- Two drugs used to treat breast cancer and osteoporosis eliminated cervical cancer in mice, according to a new study.

The drugs also cleared precancerous growths in the cervix and vagina, and prevented the onset of cancer in mice with precancerous lesions.

The breast cancer drug fulvestrant and the breast cancer/osteoporosis drug raloxifene were given to mice genetically engineered to carry human papillomavirus (HPV) 16, which is strongly associated with cervical cancer. Both drugs prevent estrogen from working in cells. Fulvestrant is marketed for women as Faslodex, and raloxifene is marketed as Evista.

The study appears in this week's issue of the Proceedings of the National Academy of Sciences.

"We have begun to test whether the drugs are as effective in treating cervical cancer in human cells as they are in our mice," senior study author Dr. Paul F. Lambert, an oncology professor at the University of Wisconsin School of Medicine and Public Health, said in a university news release.

If the lab studies, expected to take one or two years, are successful, they could be followed quickly by clinical trials, the researchers said.

Nearly all cervical cancers test positive for HPV 16, Lambert said, but not all women infected with HPV get cervical cancer, which has led researchers to examine other factors.

"Since the cervix and other female reproductive organs are so responsive to estrogen, our lab and others began to focus on that hormone," he explained.

Fulvestrant and raloxifene block a receptor (estrogen receptor alpha) that mediates estrogen function in cells.

"We can't be sure how the science will translate from animals to humans, but we have faith in our mouse model," Lambert said. "There are many similarities in how cervical cancer develops and manifests itself in women and in mice."

More information

The U.S. National Women's Health Information Center has more about cervical cancer.

SOURCE: University of Wisconsin, news release, Nov. 9, 2009

More news in Breast Cancer...

BigHealthTree.com Disclaimer

Bighealthtree.com Does Not Provide Medical Advice. This site, including the above information, is for informational purposes only and is not a substitute for professional medical or health advice. Always seek the advice of your physician or a qualified health or medical professional before starting any new treatment, changing existing treatment, or altering your current exercise and/or diet program. If you think you are having a medical emergency, call 911 (or the emergency services in your area) or your doctor immediately.

Rating: 3.2 / 5 (15 votes)